These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18436739)

  • 1. Role of decorin in the antimyeloma effects of osteoblasts.
    Li X; Pennisi A; Yaccoby S
    Blood; 2008 Jul; 112(1):159-68. PubMed ID: 18436739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
    Terpos E
    Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small leucine-rich proteoglycans in the aging skeleton.
    Young MF; Bi Y; Ameye L; Xu T; Wadhwa S; Heegaard A; Kilts T; Chen XD
    J Musculoskelet Neuronal Interact; 2006; 6(4):364-5. PubMed ID: 17185826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
    Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
    Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
    Zi FM; He JS; Li Y; Wu C; Wu WJ; Yang Y; Wang LJ; He DH; Yang L; Zhao Y; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Biol Ther; 2014 Oct; 15(10):1413-22. PubMed ID: 25046247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of brucine on bone metabolism in multiple myeloma.
    Ma Y; Zhao J; Wang Y; Li Z; Feng J; Ren H
    Mol Med Rep; 2012 Aug; 6(2):367-70. PubMed ID: 22614932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of bortezomib on bone disease in patients with multiple myeloma.
    Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
    Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.
    Li X; Ling W; Khan S; Yaccoby S
    J Bone Miner Res; 2012 Aug; 27(8):1635-48. PubMed ID: 22460389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
    De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
    Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
    Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
    Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
    Chen L; Wang S; Zhou Y; Wu X; Entin I; Epstein J; Yaccoby S; Xiong W; Barlogie B; Shaughnessy JD; Zhan F
    Blood; 2010 Jan; 115(1):61-70. PubMed ID: 19837979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblastogenesis and tumor growth in myeloma.
    Yaccoby S
    Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
    Stuhler G; Nekova TS
    Blood; 2014 Jul; 124(4):657-8. PubMed ID: 25061173
    [No Abstract]   [Full Text] [Related]  

  • 20. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.